Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas.
Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas.
复制标题
DOI：
10.3390/vetsci9080427
复制
发表时间：
2022-08-12
影响因子：
2.4
通讯作者：
Luján Feliu-Pascual A
中科院分区：
文献类型：
--
作者：
Hidalgo Crespo E;Farré Mariné A;Pumarola I Battle M;Borrego Massó JF;Luján Feliu-Pascual A
浸润性脑肿瘤在狗中很常见。尽管已经使用了不同的治疗方法，如手术、放疗、化疗或联合治疗，但缺乏最有效的治疗指南。在这项研究中，我们报告了手术联合化疗对14只浸润性胶质瘤狗生存的影响。四只狗做了两到三次手术来切除肿瘤，只有一只狗在第二次手术后不久死亡。所有人都能耐受手术，病情轻微或没有恶化，由于肿瘤进展，所有人都在诊断后6个月至2年内被安乐死。总之，手术和化疗，虽然不能治愈，但可以延长患有浸润性脑肿瘤的狗的生存期。这些信息可能有助于未来研究这种衰弱状况的最合适的治疗方法。 颅内胶质瘤预后差，最合适的治疗方法尚未确定。本回顾性研究的目的是报告一组经组织学证实的颅内胶质瘤犬接受手术减瘤和辅助替莫唑胺化疗后的进展时间和生存时间。审查了2014年至2021年在单一转诊兽医医院治疗的所有病例。入选标准包括颅内胶质瘤的组织病理学诊断、连续化疗和随访至死亡。如果主人拒绝化疗或临床记录中的随访信息不足，则将病例排除。纳入了14只客户拥有的犬，中位至进展时间（MTP）为156天（95% CI 133-320天），中位生存时间（MST）为240天（95% CI 149-465天）。替莫唑胺是一线辅助化疗，但当临床体征怀疑肿瘤复发或经高级影像学证实时，则改用另一种化疗药物（洛莫司汀、磷酸托西拉尼或美法仑）。在14只狗中，有3只接受了两次手术切除和一次，三次手术。两次手术治疗的三只犬的生存时间（ST）分别为241、428和468天，三次手术治疗的犬为780天。一次手术的狗的存活时间为181天。1例病例在发生吸入性肺炎后实施安乐死，所有其他病例在由于疑似或确诊肿瘤复发导致临床体征进展后实施安乐死。总之，本研究的结果表明，减瘤手术和辅助化疗是颅内胶质瘤犬的耐受性良好的选择，其中手术是一种可能性，应被视为一种潜在的治疗选择。对于选定的病例，可考虑重复手术。
Infiltrative brain tumours are common in dogs. Although different treatments have been used, such as surgery, radiotherapy, chemotherapy, or combinations, guidelines for the most effective management are lacking. In this study, we report the effect of combining surgery and chemotherapy on the survival of 14 dogs with infiltrative gliomas. Four dogs were operated on two or three times to remove the tumors, and only one of these dogs died shortly after the second surgery. All tolerated the surgery with minimal or no deterioration, and all were euthanized between 6 months to 2 years after diagnosis due to tumour progression. To conclude, surgery and chemotherapy, although not curative, can prolong survival in dogs with infiltrative brain tumours. This information may help future research into the most appropriate treatment for this debilitating condition. Intracranial gliomas are associated with a poor prognosis, and the most appropriate treatment is yet to be defined. The objectives of this retrospective study are to report the time to progression and survival times of a group of dogs with histologically confirmed intracranial gliomas treated with surgical debulking and adjuvant temozolomide chemotherapy. All cases treated in a single referral veterinary hospital from 2014 to 2021 were reviewed. Inclusion criteria comprised a histopathological diagnosis of intracranial glioma, adjunctive chemotherapy, and follow-up until death. Cases were excluded if the owner declined chemotherapy or there was insufficient follow-up information in the clinical records. Fourteen client-owned dogs were included with a median time to progression (MTP) of 156 days (95% CI 133–320 days) and median survival time (MST) of 240 days (95% CI 149–465 days). Temozolomide was the first-line adjuvant chemotherapy but changed to another chemotherapy agent (lomustine, toceranib phosphate, or melphalan) when tumour relapse was either suspected by clinical signs or confirmed by advanced imaging. Of the fourteen dogs, three underwent two surgical resections and one, three surgeries. Survival times (ST) were 241, 428, and 468 days for three dogs treated twice surgically and 780 days for the dog treated surgically three times. Survival times for dogs operated once was 181 days. One case was euthanized after developing aspiration pneumonia, and all other cases after progression of clinical signs due to suspected or confirmed tumour relapse. In conclusion, the results of this study suggest that debulking surgery and adjuvant chemotherapy are well-tolerated options in dogs with intracranial gliomas in which surgery is a possibility and should be considered a potential treatment option. Repeated surgery may be considered for selected cases.
登录
查看更多内容
理解Kaplan-Meier曲线的实用指南。
影响因子：
3.4
作者：
Rich, Jason T.;Neely, J. Gail;Paniello, Randal C.;Voelker, Courtney C. J.;Nussenbaum, Brian;Wang, Eric W.
通讯作者：
Wang, Eric W.
影响因子：
2.2
作者：
Rodenas, Sergio;Pumarola, Marti;Anor, Sonia
通讯作者：
Anor, Sonia
影响因子：
2.1
作者：
Moirano, Steven J.;Dewey, Curtis W.;Yang, Jun
通讯作者：
Yang, Jun
影响因子：
1.7
作者：
Hicks, Jill;Platt, Simon;Kaplan, Edward
通讯作者：
Kaplan, Edward
影响因子：
2.6
作者：
Hu H;Barker A;Harcourt-Brown T;Jeffery N
通讯作者：
Jeffery N